GENEVA, April 5 -- REMEGEN CO., LTD. (No. 58 Beijing Middle Road, Yantai Development Zone, Yantai District, China (Shandong) Pilot Free Trade ZoneYantai, Shandong 264006), 荣昌生物制药（烟台）股份有限公司 (中国山东省烟台市中国（山东）自由贸易试验区烟台片区烟台开发区北京中路58号) filed a patent application (PCT/CN2024/121600) for "METHOD FOR TREATING ANTIBODY-MEDIATED REJECTION USING TACI-FC FUSION PROTEIN" on Sep 27, 2024. With publication ...